NCT02228772View on ClinicalTrials.gov

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

November 30, 2019

Conditions
Acute Lymphoblastic LeukemiaLymphoblastic LymphomaB-cell Adult Acute Lymphoblastic LeukemiaT-cell Adult Acute Lymphoblastic Leukemia
Interventions
DRUG

MLN 9708

Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.

DRUG

Vincristine

Standard chemotherapy dosage and duration

DRUG

Cytarabine

Standard chemotherapy dosage and duration

DRUG

Doxorubicin

Standard chemotherapy dosage and duration

DRUG

Mercaptopurine

Standard chemotherapy dosage and duration

DRUG

Cyclophosphamide

Standard chemotherapy dosage and duration

DRUG

Methotrexate

Standard chemotherapy dosage and duration

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER